Skip to main content

Table 3 Change in clinical status before and after switching

From: Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO) study

  Before switching After switching
  OLZ-RIS (n=162) RIS-OLZ (n=136) OLZ-RIS (n=162) RIS-OLZ (n=136)
Change in CGI-overall score from baseline a (Mean ± SD) −0.75±1.05 −0.71±1.20 −1.15±1.12 −1.46±1.29
EPS b (%) 15.2 28.4 15.2 9.0
Loss of libido b (%) 28.8 37.8 31.3 26.7
Impotence/sexual dysfunction b (%) 18.9 29.3 22.0 19.6
Amenorrhoea/galactorrhea a (%) 12.0 12.6 17.7 5.9
Change in weight (kg) from baseline c (Mean ± SD) 3.14±6.05 1.43±4.21 4.11±8.39 1.95±8.90
  1. aThe difference between before and after switching was significant in both groups (p<0.05).
  2. bThe difference between before and after switching was significant only in patients who switched to olanzapine (i.e., the RIS-OLZ group).
  3. cThe difference between before and after switching was not significant in either group.
  4. OLZ-RIS: Patients who switched from olanzapine to risperidone.
  5. RIS-OLZ: Patients who switched from risperidone to olanzapine.
  6. EPS: Extrapyramidal Symptom.